News

According to Unity Biotechnology, its trial for the small molecule inhibitor of Bcl-xL found improvement in visual acuity and central subfield thickness observed in diabetic macular edema and wet age-related macular degeneration patients treated with UBX1325.

Clues to diagnosis from patient/family histories, examination techniques.

The company, formerly called BELKIN Laser, announced Thursday that it will begin operating under the new name BELKIN Vision.

Physicians in India have reported 7,200 documented cases of mucormycosis infections in patients with severe COVID-19 infections.

Physicians should hospitalize ON patients to prevent blindness, possible death.

Trial shows treatment has acceptable safety profile, may improve visual function.

ASCRS has issued a statement calling on Aetna to drop a new prior authorization policy it implemented last week that delays cataract surgeries.

Ex vivo experiment identifies potential benefit for supplementary oxygen.

Technology enables physicians to provide and receive important information more quickly.

Much of today’s surgical refuse is due to the single use of virtually everything.

The American Medical Association recently announced policies adopted by physician and medical student leaders from all corners of medicine on the final day of the Special Meeting of the AMA House of Delegates.

In an observational study, investigators are looking at the role of antibody secreting plasmablasts and GC B cells induced by the COVID-19 vaccines.

Ophthalmologists seek methods to control postoperative inflammation.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

FDA approval of teprotumumab as therapeutic offers hope for patients.

Knowledge of tools used in data interpretation helps clinicians trust accuracy of findings.

MedShr Insights has developed an early warning system that applies natural language processing, artificial intelligence, and machine learnings.

The company’s IASAB will identify key business initiatives, ensuring they align with its strategic vision.

Investigators find little difference between the options.

AAO develops task forces to evaluate academy, review outcomes in ophthalmology.

Novel treatments are now shifting paradigm in care of retinal diseases.

Check out the latest cartoon!

Santen Inc. announced Thursday that the U.S. FDA has approved Verkazia (cyclosporine ophthalmic emulsion) 0.1% eye drops to treat vernal keratoconjunctivitis (VKC).

Patients who are members of racial and ethnic minority groups present clinically with worse objective measures of dry eye than patients who do not belong to these groups, new research shows.

Retinal imaging tests are providing material to train and test decision-support systems.

If approved, PDS ranibizumab would become the first and only eye implant with continuous drug delivery offering people with wet AMD.